Seattle Genetics and Astellas gain Breakthrough Designation for urothelial cancer treatment
The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
